Emtricitabine/Efavirenz/Tenofovir disoproxil phosphate

恩曲他滨/依非韦伦/替诺福韦磷酸酯

Report date: 2022/12/07 18:09:04

Base Information

Drug NameEmtricitabine/Efavirenz/Tenofovir disoproxil phosphate
Drug Alias NameEfavirenz+Emtricitabine+Tenofovir Disoproxil Phosphate
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHuman immunodeficiency virus type 1 reverse transcriptase inhibitorsReverse transcriptase inhibitors
TargetsHuman immunodeficiency virus type 1 reverse transcriptaseReverse transcriptase
Therapy Area/IndicationsHIV InfectionsTuberculosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto RicoTanzania
CombinationsYes EfavirenzEmtricitabineTenofovir disoproxil phosphate
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesZentiva As
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRadboud University Medical CenterRush University Medical CenterGilead Sciences Inc +[4] 
Active IndicationsN/A
Inactive IndicationsHIV InfectionsTuberculosis

Other Information

ATC CodeN/A
Related LinksN/A